Traduction de «side-effects of bupropion » (Néerlandais → Français) :

Odds ratio of NRT versus control: 1.67 Odds ratio of bupropion versus control: 2.1 Odds ratio of NRT+bupropion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+bupropion: 0.0805 treated quit rate for brief advice+bupropion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+bupropion: 0.1892 treated quit rate for counselling+bupropion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.
Odds ratio of NRT versus control: 1.67 Odds ratio of Buproprion versus control: 2.1 Odds ratio of NRT+Buproprion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+Buproprion: 0.0805 treated quit rate for brief advice+Buproprion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+Buproprion: 0.1892 treated quit rate for counselling+Buproprion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.

Als we Bupropion vergelijken met nicotinevervangende therapie (NVT), is er beperkt bewijs dat Bupropion meer effect heeft, met name 13% meer rokers die stoppen met Bupropion, maar dit werd vastgesteld bij slechts één RCT. 8 Het betrouwbaarheidsinterval is vrij breed en benadert een klinisch weinig relevant niveau (95% CI 2 – 15).
Si l'on compare le Bupropion aux traitements nicotiniques de substitution (TNS), il semble évident que le Bupropion ait certains effets, à savoir 13% d'abstinents en plus avec le Bupropion, mais on ne le trouve que dans un RCT 8 et l'intervalle de confiance est relativement étendu : il s'approche du niveau clinique et devient ininterprétable(95% CI 2 – 15).

Costs and consequences of side-effects of bupropion or NRT were not taken into account
Costs and consequences of side-effects of Buproprion or NRT were not taken into account

patients remain on one type of treatment throughout their smoking cessation therapy costs and consequences of side-effects of bupropion or NRT were not taken into account
patients remain on one type of treatment throughout their smoking cessation therapy costs and consequences of side-effects of Buproprion or NRT were not taken into account

36. Woolacott NF, Jones L, Forbes CA, Mather LC, Sowden AJ, Song FJ et al. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation.
36. Woolacott NF, Jones L, Forbes CA, Mather LC, Sowden AJ, Song FJ et al. The clinical effectiveness and cost-effectiveness of Bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation.

Bupropion wordt beschouwd als het meest kosteneffectieve middel, met uiteindelijk een beter effect waarbij kleinere hoeveelheden van het dure geneesmiddel nodig zijn.
On pense que le Bupropion est plus rentable, en raison des meilleurs effets et des volumes inférieurs nécessaires de ce médicament plus coûteux.

hypotensie + memantine: toename van de ongewenste dopaminerge effecten + bupropion: neuropsychische stoornissen (te vermijden) + baclofen: neuropsychische en gastro-intestinale stoornissen (te vermijden) + methyldopa: verhoogt het effect van levodopa (te vermijden)
du risque d’hypotension orthostatique + mémantine: renforcement des effets indésirables dopaminergiques + bupropion: troubles neuropsychiques (à éviter) + baclofène: troubles neuropsychiques et digestifs (à éviter) + methyldopa: augmentation des effets de la lévodopa (à éviter)

39. Hatsukami DK, Rennard S, Patel MK, Kotlyar M, Malcolm R, Nides MA et al. Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking.
39. Hatsukami DK, Rennard S, Patel MK, Kotlyar M, Malcolm R, Nides MA et al. Effects of sustained-release Bupropion among persons interested in reducing but not quitting smoking.

Gecommentarieerd Geneesmiddelenrepertorium 34 , Farmacotherapeutisch Kompas 35 , British National Formulary 36 , Martindale 37 , Meyler’s Side Effects of Drugs 38 , Geriatric Dosage Handbook 39 , Managing Clinically Important Drug Interactions 40 , Drug Information AHFS 41 .
Commenté des Médicaments 34 , Farmacotherapeutisch Kompas 35 , British National Formulary 36 , Martindale 37 , Meyler’s Side Effects of Drugs 38 , Geriatric Dosage Handbook 39 , Managing Clinically Important Drug Interactions 40 , Drug Information AHFS 41 .

(O’Connell 2009) O’Connell K, Davis AR, Kerns J. Oral contraceptives: side effects and depression in adolescent girls. Contraception
(O’Connell 2009) O’Connell K, Davis AR, Kerns J. Oral contraceptives: side effects and depression in adolescent girls.